Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion

• Published in: The Pediatric infectious disease journal Vol. 18; no. 3; pp. 223 - 231
• Main Authors: MEISSNER, H CODY, WELLIVER, ROBERT C, CHARTRAND, STEPHAN A, LAW, BARBARA J, WEISMAN, LEONARD E, DORKIN, HENRY L, RODRIGUEZ, WILLIAM J
• Format: Journal Article
• Language: English
• Published: Baltimore, MD Lippincott Williams & Wilkins, Inc 01-03-1999; Philadelphia, PA Lippincott; Hagerstown, MD
• Subjects: Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Biological and medical sciences; Human viral diseases; Humans; Infant; Infant, Newborn; Infant, Premature; Infectious diseases; Medical sciences; Palivizumab; Respiratory Syncytial Virus Infections - prevention & control; Respiratory Syncytial Viruses - immunology; Risk Factors; Viral diseases; Viral diseases of the respiratory system and ent viral diseases; Human respiratory syncytial virus; Indication; Vaccination; Infant; Monoclonal antibody; Paramyxoviridae; Prevention; Palivizumab; Heart disease; Obstructive pulmonary disease; Pneumovirus; Pancreatic disease; Human; Lung disease; Pneumovirinae; Congenital; Respiratory disease; Metabolic diseases; Cystic fibrosis; Immune deficiency; Recommendation; Genetic disease; Asthma; Virus; Immunoprophylaxis; Mononegavirales; Prematurity; Risk factor; Digestive diseases; Pharmacokinetics; Pneumopathy
• ISSN: 0891-3668; 1532-0987
• DOI: 10.1097/00006454-199903000-00004